Enanta Pharmaceuticals (ENTA) Financials: History & Chart

Enanta Pharmaceuticals, Inc.(ENTA)

Biotechnology · Watertown, MA

$12.36-0.24 (-1.94%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Watertown, MA

120 employees

www.enanta.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jay R. Luly

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	65.26M	14.36M	17.16M	18.61M	15.13M	18.31M	14.93M	16.96M	14.61M
Cost of Goods Sold	1.21M	0.00	1.21M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	64.05M	14.36M	15.95M	18.61M	15.13M	18.31M	14.93M	16.96M	14.61M
Gross Profit Margin	98.1%	100.0%	93.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	122.78M	31.59M	27.80M	29.87M	33.51M	37.21M	39.45M	40.50M	44.46M
Research & Development	86.24M	22.13M	19.44M	20.86M	23.81M	27.21M	28.07M	27.66M	30.78M
Selling, General & Administrative	37.75M	9.47M	9.57M	9.01M	9.70M	10.00M	11.39M	12.85M	13.68M
Operating Income (EBIT)	-58.73M	-17.24M	-11.85M	-11.25M	-18.39M	-18.89M	-24.53M	-23.54M	-29.85M
Operating Margin	-90.0%	-120.0%	-69.1%	-60.5%	-121.6%	-103.2%	-164.3%	-138.8%	-204.4%
Income Before Tax (EBT)	-63.13M	-19.46M	-13.08M	-11.91M	-18.67M	-18.23M	-23.95M	-22.71M	-29.19M
Interest Income	6.61M	N/A	2.08M	2.42M	2.10M	2.29M	2.29M	2.80M	3.18M
Interest Expense	12.92M	4.13M	3.32M	3.08M	2.39M	1.62M	1.71M	1.96M	2.58M
Other Income/Expense	-4.40M	-2.23M	-1.23M	-661K	-282K	667K	578K	837K	668K
Net Income	-63.23M	-19.50M	-13.09M	-11.94M	-18.70M	-18.25M	-22.64M	-22.29M	-28.82M
Income Tax Expense	99K	36K	7K	24K	32K	29K	-1.30M	-416K	-363K
Net Profit Margin	-96.9%	-135.8%	-76.3%	-64.1%	-123.6%	-99.7%	-151.7%	-131.4%	-197.3%
EBITDA	-53.82M	-16.05M	-10.64M	-10.02M	-17.10M	-17.68M	-23.32M	-22.65M	-29.38M
EBITDA Margin	-82.5%	-111.8%	-62.0%	-53.8%	-113.1%	-96.6%	-156.3%	-133.6%	-201.1%
Depreciation & Amortization	4.91M	1.19M	1.21M	1.23M	1.28M	1.21M	1.20M	889K	479K
EPS Basic	-2.41	-0.67	-0.45	-0.42	-0.87	-0.86	-1.06	-1.05	-1.36
EPS Diluted	-2.41	-0.67	-0.45	-0.42	-0.87	-0.86	-1.06	-1.05	-1.36
Weighted Average Basic Shares	29.09M	29.09M	29.04M	28.75M	21.38M	21.32M	21.36M	21.24M	21.19M
Weighted Average Diluted Shares	29.09M	29.09M	29.04M	28.75M	21.38M	21.32M	21.36M	21.24M	21.19M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	09/30/2025	09/30/2024	09/30/2023	09/30/2022	09/30/2021	09/30/2020	09/30/2019	09/30/2018
Revenue	65.32M	67.64M	79.20M	86.16M	97.07M	122.47M	205.20M	206.63M
Cost of Goods Sold	4.59M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	60.74M	67.64M	79.20M	86.16M	97.07M	122.47M	205.20M	206.63M
Gross Profit Margin	93.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	146.09M	189.33M	216.41M	210.00M	206.65M	164.11M	168.46M	118.30M
Research & Development	106.74M	131.48M	163.52M	164.52M	174.11M	136.76M	142.21M	94.86M
Selling, General & Administrative	43.93M	57.85M	52.89M	45.48M	32.54M	27.36M	26.25M	23.44M
Operating Income (EBIT)	-85.35M	-121.69M	-137.21M	-123.84M	-109.57M	-41.64M	36.74M	88.33M
Operating Margin	-130.7%	-179.9%	-173.2%	-143.7%	-112.9%	-34.0%	17.9%	42.7%
Income Before Tax (EBT)	-83.55M	-117.79M	-131.00M	-122.19M	-107.58M	-35.02M	45.56M	93.12M
Interest Income	9.48M	14.77M	11.36M	1.57M	2.02M	6.47M	8.82M	N/A
Interest Expense	7.68M	10.94M	5.15M	N/A	N/A	N/A	N/A	4.85M
Other Income/Expense	1.80M	3.90M	6.21M	1.66M	1.99M	6.62M	8.82M	4.79M
Net Income	-81.89M	-116.05M	-133.82M	-121.75M	-79.00M	-36.17M	46.38M	71.96M
Income Tax Expense	-1.66M	-1.74M	2.82M	-433K	-28.58M	1.15M	-826K	21.16M
Net Profit Margin	-125.4%	-171.6%	-169.0%	-141.3%	-81.4%	-29.5%	22.6%	34.8%
EBITDA	-80.26M	-119.36M	-134.84M	-120.87M	-106.24M	-37.99M	40.00M	90.85M
EBITDA Margin	-122.9%	-176.5%	-170.2%	-140.3%	-109.4%	-31.0%	19.5%	44.0%
Depreciation & Amortization	5.09M	2.34M	2.37M	2.97M	3.33M	3.64M	3.26M	2.52M
EPS Basic	-3.84	-5.48	-6.38	-5.91	-3.92	-1.81	2.37	3.48
EPS Diluted	-3.84	-5.48	-6.38	-5.91	-3.92	-1.81	2.21	3.48
Weighted Average Basic Shares	21.34M	21.16M	20.97M	20.60M	20.17M	19.94M	19.58M	20.65M
Weighted Average Diluted Shares	21.34M	21.16M	20.97M	20.60M	20.17M	19.94M	20.97M	20.65M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.